Paul Richardson | | KESÄKUU 18, 2019
Despite recent advances in MM therapy, the disease remains incurable. Patients with late-stage RRMM refractory to pomalidomide and/or daratumumab have limited effective treatment options. Melflufen is a novel peptide-conjugated alkylator potentiated by intracellular aminopeptidases, which are markedly overexpressed in multiple myeloma.
In this MEDtalk Paul G. Richardson present updated efficacy and safety of melflufen + low-dose dexamethasone in patients refractory to pomalidomide and/or daratumumab (HORIZON-study).